SOD1 in Cerebral Spinal Fluid as a Pharmacodynamic Marker for Antisense Oligonucleotide Therapy

JAMA Neurology - United States
doi 10.1001/jamaneurol.2013.593
Full Text
Abstract

Available in full text

Categories
Neurology
Date
Authors
Publisher

American Medical Association (AMA)

Related search

Antisense Oligonucleotide Therapy for Neurodegenerative Disease

Journal of Clinical Investigation
Medicine
2006English

Antisense Oligonucleotide Gene Therapy for Neuromuscular Disorders

University of Ottawa Journal of Medicine
2018English

NCALD Antisense Oligonucleotide Therapy in Addition to Nusinersen Further Ameliorates Spinal Muscular Atrophy in Mice

American Journal of Human Genetics
Genetics
2019English

In Vivo Imaging as a Pharmacodynamic Marker

Clinical Cancer Research
Cancer ResearchOncology
2014English

124. AAV-Mediated Antisense Oligonucleotide-Based Therapy for CEP290-Associated LCA

Molecular Therapy
Molecular MedicineMolecular BiologyPharmacologyMedicineGeneticsDrug Discovery
2014English

Antisense Oligonucleotide Hope for Childhood Epilepsies

Nature Reviews Neurology
Molecular NeuroscienceNeurologyCellular
2020English

Antisense Oligonucleotide Treatment for Human Astrocytoma

Genome Biology
2001English

A Multi-Targeted Antisense Oligonucleotide-Based Therapy Directed at Phosphodiesterases 4 and 7 for COPD

2012English

Figure 1: ATF4 as a Pharmacodynamic Marker in Nontransgenic and hAPP-J20 Mice.

English

Amanote Research

Note-taking for researchers

Follow Amanote

© 2024 Amaplex Software S.P.R.L. All rights reserved.

Privacy PolicyRefund Policy